NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment
News
NICE issued its final draft guidance recommending enzalutamide (Xtandi, by Astellas Pharma) for prostate cancer (PC) patients who have already tried first-line treatments with no success, for those who have none ... Read more